论文部分内容阅读
目的:探讨曲妥珠单抗对HER-2过表达乳腺癌细胞株mTOR信号通路的影响。方法:在培养的乳腺癌细胞株MDA-MB-453中加入曲妥珠单抗,采用蛋白质印迹法检测细胞中mTOR、S6、4EBP1和Akt的蛋白磷酸化水平,同时检测该药对MDA-MB-453增殖及克隆形成的影响。结果:乳腺癌细胞株MDA-MB-453在加入曲妥珠单抗作用下,mTOR、S6、4EBP1和Akt磷酸化明显受抑制,并具有浓度依赖性;乳腺癌细胞株MDA-MB-453在加入曲妥珠单抗后,细胞相对增殖率随着药物浓度增大由(77±6.3)%降至(21±1.5)%,克隆形成率随着药物浓度增大由(55±4)%降至(4±1)%。结论:曲妥珠单抗可通过抑制mTORC1和mTORC2信号通路,从而抑制乳腺癌细胞株MDA-MB-453的生长与增殖。
Objective: To investigate the effect of trastuzumab on the mTOR signaling pathway in HER-2 overexpressing breast cancer cell lines. Methods: Trastuzumab was added to the cultured breast cancer cell line MDA-MB-453. The protein phosphorylation of mTOR, S6, 4EBP1 and Akt in the cells was detected by Western blotting. -453 proliferation and clonal formation. Results: The phosphorylation of mTOR, S6, 4EBP1 and Akt was significantly inhibited in MDA-MB-453 breast cancer cell line MDA-MB-453 in a concentration-dependent manner. After adding trastuzumab, the cell proliferation rate decreased from (77 ± 6.3)% to (21 ± 1.5)% with the increase of drug concentration, and the rate of clone formation increased from (55 ± 4)% To (4 ± 1)%. Conclusion: Trastuzumab can inhibit the growth and proliferation of breast cancer cell line MDA-MB-453 by inhibiting the mTORC1 and mTORC2 signaling pathways.